Characterization of a Novel Glucocorticoid-resistant Human B-cell Acute Lymphoblastic Leukemia Cell Line, with AMPK, MTOR and Fatty Acid Synthesis Pathway Inhibition

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2021 Nov 26

PMID 34823530

Citations 1

Authors

Yuanyuan Li

Chuan Zuo

Ling Gu

Affiliations

Soon will be listed here.

Abstract

Background: Acquired glucocorticoid (GC) resistance remains the main obstacle in acute lymphoblastic leukemia (ALL) therapy. The aim of the present study was to establish a novel GC-resistant B-ALL cell line and investigate its biological characteristics.

Methods: A cell culture technique was used to establish the GC-resistant cell line from the parental cell, NALM-6. Molecular and cellular biological techniques including flow cytometry, MTT assay, western blotting, DNA fingerprinting analysis and whole transcriptome sequencing (WTS) were used to characterize the GC-resistant cell lines. Nude mice were used for xenograft studies.

Results: The GC-resistant cell line, NALM-6/HDR, was established by culturing NALM-6 cells under hypoxia for 5 weeks with a single dexamethasone (Dex) treatment. We subcloned the NALM-6/HDR cell lines, and got 6 monoclone Dex-resistant cell lines, NALM-6/HDR-C1, C3, C4, C5, C6 and C9 with resistance index (RI) ranging from 20,000-50,000. NALM-6/HDR and its monoclone cell line, NALM-6/HDR-C5, exhibited moderate (RI 5-15) to high resistance (RI > 20) to Ara-c; low or no cross-resistance to L-Asp, VCR, DNR, and MTX (RI < 5). STR analysis confirmed that NALM-6/HDR and NALM-6/H were all derived from NALM-6. All these cells derived from NALM-6 showed similar morphology, growth curves, immunophenotype, chromosomal karyotype and tumorigenicity. WTS analysis revealed that the main metabolic differences between NALM-6 or NALM-6/H (GC-sensitive) and NALM-6/HDR (GC-resistant) were lipid and carbohydrates metabolism. Western blotting analysis showed that NALM-6/HDR cells had a low expression of GR and p-GR. Moreover, AMPK, mTORC1, glycolysis and de novo fatty acid synthesis (FAS) pathway were inhibited in NALM-6/HDR when compared with NALM-6.

Conclusions: NALM-6/HDR cell line may represent a subtype of B-ALL cells in patients who acquired GC and Ara-c resistance during the treatment. These patients may get little benefit from the available therapy target of AMPK, mTORC1, glycolysis and FAS pathway.

Citing Articles

Ruxolitinib inhibits the proliferation and induces the apoptosis of MLL-r ALL cells through inactivating JAK/STAT signaling pathway.

Liao X, Zhou D, Fang J, Qiu K Transl Pediatr. 2023; 12(6):1088-1097.

PMID: 37427069 PMC: 10326758. DOI: 10.21037/tp-23-16.

References

Butler L, Perone Y, Dehairs J, Lupien L, de Laat V, Talebi A . Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention. Adv Drug Deliv Rev. 2020; 159:245-293. PMC: 7736102. DOI: 10.1016/j.addr.2020.07.013. View

Rohrig F, Schulze A . The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer. 2016; 16(11):732-749. DOI: 10.1038/nrc.2016.89. View

Olivas-Aguirre M, Torres-Lopez L, Pottosin I, Dobrovinskaya O . Overcoming Glucocorticoid Resistance in Acute Lymphoblastic Leukemia: Repurposed Drugs Can Improve the Protocol. Front Oncol. 2021; 11:617937. PMC: 7991804. DOI: 10.3389/fonc.2021.617937. View

Tissing W, Meijerink J, den Boer M, Pieters R . Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia. Leukemia. 2003; 17(1):17-25. DOI: 10.1038/sj.leu.2402733. View

Kishton R, Barnes C, Nichols A, Cohen S, Gerriets V, Siska P . AMPK Is Essential to Balance Glycolysis and Mitochondrial Metabolism to Control T-ALL Cell Stress and Survival. Cell Metab. 2016; 23(4):649-62. PMC: 4832577. DOI: 10.1016/j.cmet.2016.03.008. View

Icard P, Lincet H . The reduced concentration of citrate in cancer cells: An indicator of cancer aggressiveness and a possible therapeutic target. Drug Resist Updat. 2016; 29:47-53. DOI: 10.1016/j.drup.2016.09.003. View

Quentmeier H, Pommerenke C, Dirks W, Eberth S, Koeppel M, MacLeod R . The LL-100 panel: 100 cell lines for blood cancer studies. Sci Rep. 2019; 9(1):8218. PMC: 6547646. DOI: 10.1038/s41598-019-44491-x. View

Inoki K, Kim J, Guan K . AMPK and mTOR in cellular energy homeostasis and drug targets. Annu Rev Pharmacol Toxicol. 2011; 52:381-400. DOI: 10.1146/annurev-pharmtox-010611-134537. View

Basappa J, Citir M, Zhang Q, Wang H, Liu X, Melnikov O . ACLY is the novel signaling target of PIP/PIP and Lyn in acute myeloid leukemia. Heliyon. 2020; 6(5):e03910. PMC: 7218026. DOI: 10.1016/j.heliyon.2020.e03910. View

10.

Humbert M, Seiler K, Mosimann S, Rentsch V, Sharma K, Pandey A . Reducing FASN expression sensitizes acute myeloid leukemia cells to differentiation therapy. Cell Death Differ. 2021; 28(8):2465-2481. PMC: 8329134. DOI: 10.1038/s41418-021-00768-1. View

11.

Svensson R, Parker S, Eichner L, Kolar M, Wallace M, Brun S . Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models. Nat Med. 2016; 22(10):1108-1119. PMC: 5053891. DOI: 10.1038/nm.4181. View

12.

Xiao H, Ding Y, Gao Y, Wang L, Wang H, Ding L . Haploinsufficiency of drives glucocorticoid resistance in adult acute lymphoblastic leukemia cells by down-regulating the mitochondrial apoptosis axis, and is sensitive to Bcl-2 blockage. Cancer Cell Int. 2019; 19:218. PMC: 6708234. DOI: 10.1186/s12935-019-0940-9. View

13.

Drexler H, Quentmeier H . The LL-100 Cell Lines Panel: Tool for Molecular Leukemia-Lymphoma Research. Int J Mol Sci. 2020; 21(16). PMC: 7461097. DOI: 10.3390/ijms21165800. View

14.

Greenstein S, Ghias K, Krett N, Rosen S . Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clin Cancer Res. 2002; 8(6):1681-94. View

15.

Inaba H, Pui C . Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 2010; 11(11):1096-106. PMC: 3309707. DOI: 10.1016/S1470-2045(10)70114-5. View

16.

Icard P, Wu Z, Fournel L, Coquerel A, Lincet H, Alifano M . ATP citrate lyase: A central metabolic enzyme in cancer. Cancer Lett. 2019; 471:125-134. DOI: 10.1016/j.canlet.2019.12.010. View

17.

Bloomfield C, Smith K, Peterson B, Munck A . Glucocorticoid receptors in adult acute lymphoblastic leukemia. Cancer Res. 1981; 41(11 Pt 2):4857-60. View

18.

Abdel-Wahab A, Mahmoud W, Al-Harizy R . Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy. Pharmacol Res. 2019; 150:104511. DOI: 10.1016/j.phrs.2019.104511. View

19.

Wandler A, Huang B, Craig J, Hayes K, Yan H, Meyer L . Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia. Leukemia. 2020; 34(8):2025-2037. PMC: 7440098. DOI: 10.1038/s41375-020-0748-6. View

20.

Coley H . Development of drug-resistant models. Methods Mol Med. 2003; 88:267-73. DOI: 10.1385/1-59259-406-9:267. View